<DOC>
	<DOCNO>NCT00569179</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose alloreactive NK cell transfuse follow stem cell transplant .</brief_summary>
	<brief_title>A Phase I Trial Alloreactive Cell Infusion Following Transplantation Haplotype Cells Patients With Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Patients must histologically document AML , ALL , MDS , CML , Identification haploidentical donor LVEF &gt; 45 % correct DLCO &gt; 50 % predict Serum Creatinine &lt; = 2 mg/dL Bilirubin &lt; 2 x ULN AST , ALT &lt; 2 x ULN Age â‰¤ 65 year Performance Status 01 Patients relapse &lt; 6 month autologous SCT eligible . Patients active infection require oral intravenous antibiotic eligible enrollment resolution infection No HIV disease Nonpregnant nonnursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Myeloid Malignancies</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
	<keyword>CML</keyword>
</DOC>